Roivant Sciences (ROIV) Expected to Announce Quarterly Earnings on Monday

Key Points

• Roivant Sciences is expected to release its Q1 2026 earnings on August 11th, with forecasts showing a loss of ($0.23) per share and revenue of $6.92 million.
• In its previous quarterly report, Roivant missed earnings expectations, reporting ($0.31) EPS and revenue of $7.57 million, significantly below analyst estimates of $62.17 million.
• Recent insider activity includes major shareholder Vivek Ramaswamy selling 577,007 shares, and CEO Eric Venker selling 100,000 shares, indicating notable changes in ownership stakes.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) is anticipated to announce its Q1 2026 earnings results before the market opens on Monday, August 11th. Analysts expect Roivant Sciences to post earnings of ($0.23) per share and revenue of $6.92 million for the quarter.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The company had revenue of $7.57 million during the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative return on equity of 14.76% and a negative net margin of 225.71%. During the same quarter in the prior year, the firm posted ($0.23) EPS. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Stock Down 0.6%

Shares of Roivant Sciences stock traded down $0.07 during trading on Friday, reaching $11.49. 489,277 shares of the stock were exchanged, compared to its average volume of 5,794,031. The firm has a market cap of $7.81 billion, a price-to-earnings ratio of -45.94 and a beta of 1.15. Roivant Sciences has a 1 year low of $8.73 and a 1 year high of $13.06. The stock's fifty day moving average is $11.32 and its 200 day moving average is $10.88.

Insider Activity at Roivant Sciences

In related news, COO Eric Venker sold 566,278 shares of Roivant Sciences stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16. Following the transaction, the chief operating officer owned 1,462,223 shares in the company, valued at approximately $16,406,142.06. The trade was a 27.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $11.46, for a total value of $6,612,500.22. Following the sale, the insider owned 37,284,108 shares of the company's stock, valued at $427,275,877.68. This represents a 1.52% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 3,190,503 shares of company stock worth $36,086,546 in the last quarter. Company insiders own 10.80% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Roivant Sciences stock. Goldman Sachs Group Inc. boosted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 15.4% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 2,433,386 shares of the company's stock after buying an additional 324,764 shares during the period. Goldman Sachs Group Inc. owned approximately 0.36% of Roivant Sciences worth $24,553,000 at the end of the most recent quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ROIV shares. The Goldman Sachs Group raised Roivant Sciences to a "strong-buy" rating and set a $19.00 price objective for the company in a research report on Thursday, July 10th. HC Wainwright reiterated a "buy" rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.